Research In Brief
This article was originally published in The Gray Sheet
Executive Summary
Uterine artery embolization: BioSphere Medical's Embosphere tris-acryl gelatin microspheresare more effective in blocking blood flow to benign uterine fibroids than Boston Scientific's Contour SE polyvinyl alcohol microspheres, according to results of a study led by Gary P. Siskin, M.D., Albany Medical Center, published in the January Journal of Vascular and Interventional Radiology. In the 53-patient randomized study, co-funded by Boston Scientific and BioSphere, patients treated with Contour SE had a 29.6% treatment failure rate and 66.7% total success rate (100% occlusion of the arteries feeding the tumor), compared to a 3.8% failure rate and 92.3% success rate for Embosphere. Embosphere, already the market leader, "should be the preferred agent for UAE at this time," the authors conclude
You may also be interested in...
Olympic Cool-Cap approval
FDA approves Olympic Medical's Olympic Cool-Cap device to treat hypoxic ischemic encephalopathy in term newborns on Dec. 20. Roughly three in every 1,000 newborns are at risk of brain injury due to an interruption of blood flow and oxygen supply during labor and delivery. The device, administered within the first six hours of life, lowers body temperature 3-4 ?C to reduce brain swelling. FDA's Neurological Devices Panel voted 5-1 in favor of approval in June 2005 (1"The Gray Sheet" June 20, 2005, p. 9). As conditions of the approval, Olympic will set up a patient registry to collect information on device usage and to track treatment outcomes; organize a training and certification process for device operators; and restrict use of the device to patients who meet the eligibility criteria defined by the original study. Seattle-based Olympic, a subsidiary of Natus Medical, will market Cool-Cap via its own sales and distribution team...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.